BioSpace News Archive

The Global bone growth stimulators market has been experiencing a positive transformation for the course of years.

Fact.MR - A Market Research And Competitive Intelligence Provider, the Americas hospital acquired infection testing market was valued at US$ 595 Million in 2020, and is expected to exhibit a CAGR of around 15% over the forecast period.

According to Fact.MR, a market research and competitive intelligence provider: Newly released data on transplant pathogen monitoring in the Americas shows that the market enjoyed year-on-year growth of 6.7% in 2021.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global spinal surgical devices market is likely to witness significant growth rapidly growing aging population, growing preference for minimally invasive procedures, and advancements in medical technology.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Opioids are used for pain relief.

Wilmington, Delaware, United States, Transparency Market Research Inc.: According to Transparency Market Research’s latest report on the global medical waste management market for the historical period 2017–2019 and forecast period 2021–2028, increase in volume of healthcare waste and surge in geriatric and obese populations are projected to boost the growth of the global market during the forecast period

Wilmington, Delaware, United States, Transparency Market Research Inc.: Rise in automation in laboratories, technological advancements in laboratory information systems, need for regulatory compliance, and increase in R&D spending are the key drivers of the global laboratory information systems market.

Italfarmaco, an Italian multinational company in the chemical-pharmaceutical sector, has acquired 100% of Lacer Pharmaceuticals, one of the leading companies in Spain in the area of health and personal hygiene.

Boston Scientific Corporation generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported basis, 9.6 percent on an operational1 basis and 6.6 percent on an organic2 basis, all compared to the prior year period.

Reviva Pharmaceuticals Holdings is pleased to provide an update on key milestones related to its clinical development pipeline.